On October 8, IMPACT THERAP-B fell 8.07% in regular trading, settling at HK$13.32 with turnover of HK$27.08 million. The decline reflects substantial profit-taking following a sharp prior rally, as investors locked in gains after the company's core drug Senaparib received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use.

Despite fresh catalysts such as Senaparib's inclusion in China's national medical insurance and rapid sales ramp-up, the stock had surged on the dual boost of the European regulatory milestone and its addition to the Stock Connect program. With those positives now priced in, near-term selling pressure has emerged. The company, a commercial-stage biotechnology firm, has already secured approval in China for Senaparib as a first-line maintenance therapy for ovarian cancer and continues to advance its European market expansion.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)